{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:07Z","timestamp":1793727847716,"version":"4.6.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunomodulatory therapy in sepsis has long failed to deliver consistent clinical benefit, in part because the heterogeneity of host responses and the dynamic nature of disease trajectories have been underestimated. Rather than equating the timing of initiation with a fixed interval after symptom onset, a more clinically meaningful definition is a chronology-informed clinical decision point at which standard sepsis care has been implemented, serial monitoring supports a dominant or clinically important discordant immunophenotype, and the organ dysfunction trajectory suggests that continued observation without reassessment or escalation may be unsafe. Using this operational definition as its framework, this review synthesizes the dynamic course of immune dysregulation in sepsis, the clinical utility and limitations of key biomarkers and functional assays, and the emerging evidence from enrichment-design trials that reassess the therapeutic windows of different strategies. Current evidence suggests that intravenous corticosteroids in adult septic shock remain the immunomodulatory approach closest to routine clinical practice, whereas anakinra, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-gamma), interleukin-7 (IL-7), and programmed cell death protein 1\/programmed death-ligand 1 (PD-1\/PD-L1) blockade are more appropriately considered in biomarker-enriched settings with rigorous serial reassessment, ideally within research protocols or experienced centers. The central challenge for the future is not to identify a universal immune drug for all patients with sepsis, but to establish reproducible, bedside-applicable immune phenotyping and reassessment pathways that can determine who may benefit, from which intervention, and at what point in the disease course.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1898450","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:14:00Z","timestamp":1785323640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["When to initiate immunomodulatory therapy in sepsis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Chengdu Medical College The First Affiliated Hospital","place":["Chengdu, China"]},{"name":"School of Clinical Medicine, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Chengdu Medical College The First Affiliated Hospital","place":["Chengdu, China"]},{"name":"School of Clinical Medicine, Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00134-026-08361-1","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2026","volume":"54","author":"Prescott","year":"2026","journal-title":"Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00468-x","article-title":"Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies","volume":"12","author":"Shankar-Hari","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03956-5","article-title":"A consensus immune dysregulation framework for sepsis and critical illnesses","volume":"31","author":"Moore","year":"2025","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1477449","article-title":"Delayed macrophage targeting by clodronate liposomes worsens the progression of cytokine storm syndrome","volume":"15","author":"Khanna","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/anae.16263","article-title":"Immunomodulatory drugs in sepsis: a systematic review and meta-analysis","volume":"79","author":"Robey","year":"2024","journal-title":"Anaesthesia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkaf001","article-title":"Recent advances of precision immunotherapy in sepsis","volume":"13","author":"Arapis","year":"2025","journal-title":"Burns Trauma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100817","article-title":"Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial","volume":"3","author":"Leventogiannis","year":"2022","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24175","article-title":"Precision immunotherapy to improve sepsis outcomes: The ImmunoSep randomized clinical trial","volume":"335","author":"Giamarellos-Bourboulis","year":"2026","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21270","article-title":"Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy","volume":"90","author":"Monneret","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363oc","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial","volume":"180","author":"Meisel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cyto.b.21043","article-title":"Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples","volume":"84","author":"Demaret","year":"2013","journal-title":"Cytometry B Clin Cytom"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/shk.0000000000001443","article-title":"Pharmacokinetics, pharmacodynamics, and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1\/2 study","volume":"53","author":"Watanabe","year":"2020","journal-title":"Shock"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.001","article-title":"Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha","volume":"42","author":"Shalova","year":"2015","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400721","article-title":"NFkB2\/p100 is a key factor for endotoxin tolerance in human monocytes: a demonstration using primary human monocytes from patients with sepsis","volume":"193","author":"Cubillos-Zapata","year":"2014","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci83404","article-title":"p21 mediates macrophage reprogramming through regulation of p50-p50 NF-kappaB and IFN-beta","volume":"126","author":"Rackov","year":"2016","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/infdis\/jix279","article-title":"PD-L1 overexpression during endotoxin tolerance impairs the adaptive immune response in septic patients via HIF1alpha","volume":"217","author":"Avenda\u00f1o-Ortiz","year":"2018","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00915","article-title":"A system dynamics model to predict the human monocyte response to endotoxins","volume":"8","author":"\u00c1lvarez","year":"2017","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.chstcc.2023.100029","article-title":"Ex vivo endotoxin stimulation of blood for predicting survival in patients with sepsis: a systematic review","volume":"1","author":"Wheelwright","year":"2023","journal-title":"CHEST Crit Care"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447523","article-title":"Assessing sepsis-induced immunosuppression to predict positive blood cultures","volume":"15","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41540-024-00473-y","article-title":"Mathematical model of the inflammatory response to acute and prolonged lipopolysaccharide exposure in humans","volume":"10","author":"Relouw","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1530\/ey.15.8.12","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10485","article-title":"Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial","volume":"316","author":"Gordon","year":"2016","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial","volume":"25","author":"Opal","year":"1997","journal-title":"Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891024","article-title":"Advances in immune monitoring approaches for sepsis-induced immunosuppression","volume":"13","author":"Yao","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","article-title":"Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial","volume":"13","author":"Daix","year":"2023","journal-title":"Ann Intensive Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001090","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","volume":"2013","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12967-023-04592-8","article-title":"Efficacy of IVIG therapy for patients with sepsis: a systematic review and meta-analysis","volume":"21","author":"Pan","year":"2023","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082583","article-title":"The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial","volume":"388","author":"Wu","year":"2025","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0196","article-title":"Development and validation of the Phoenix criteria for pediatric sepsis and septic shock","volume":"331","author":"Sanchez-Pinto","year":"2024","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0179","article-title":"International consensus criteria for pediatric sepsis and septic shock","volume":"331","author":"Schlapbach","year":"2024","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s13054-020-03266-x","article-title":"Hydrocortisone treatment is associated with a longer duration of MODS in pediatric patients with severe sepsis and immunoparalysis","volume":"24","author":"Bline","year":"2020","journal-title":"Crit Care"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:14:07Z","timestamp":1785323647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1898450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1898450"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1898450","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1898450"}}